🇺🇸 FDA

Company profile · Sponsor

Apellis

Apellis Europe B.V.

APLS · NYSE pharma WALTHAM, MA, EU
Pipeline
20
Drugs
1
Patents
8

Quick answer

Apellis (APLS) is a pharma company. headquartered in WALTHAM, MA, EU. listed on NYSE. NovaPharmaNews links 20 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker APLS
Exchange NYSE
Company type pharma
Headquarters WALTHAM, MA, EU
SEC CIK 0001492422

Pipeline (20)

Search pipeline →

  1. APL-2

    Apellis

    Geographic Atrophy

    phase 3 small molecule completed

    2 trials

  2. APL-2

    Apellis

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    1 trial

  3. APL-2, Pegcetacoplan

    Apellis

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  4. APL2

    Apellis

    FSGS

    phase 3 small molecule active

    1 trial

  5. PEGCETACOPLAN (APL-2)

    Apellis

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  6. Pegcetacoplan

    Apellis

    C3G

    phase 3 small molecule active

    3 trials

  7. Pegcetacoplan

    Apellis

    PNH

    phase 3 small molecule active

    2 trials

  8. Pegcetacoplan

    Apellis

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    2 trials

  9. Pegcetacoplan

    Apellis

    Delayed Graft Function

    phase 3 small molecule active

    1 trial

  10. APL-2

    Apellis

    Warm Autoimmune Hemolytic Anemia

    phase 2 small molecule completed

    1 trial

  11. APL-2

    Apellis

    IgA Nephropathy

    phase 2 small molecule completed

    1 trial

  12. APL-3007, pegcetacoplan (APL-2)

    Apellis

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 2 small molecule active

    1 trial

  13. APL-9

    Apellis

    COVID

    phase 2 small molecule completed

    1 trial

  14. Pegcetacoplan

    Apellis

    Transplant-Associated Thrombotic Microangiopathy

    phase 2 small molecule completed

    1 trial

  15. Pegcetacoplan

    Apellis

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule active

    2 trials

  16. Pegcetacoplan

    Apellis

    Neovascular Age-related Macular Degeneration

    phase 2 small molecule terminated

    2 trials

  17. Pegcetacoplan

    Apellis

    Geographic Atrophy

    phase 2 small molecule completed

    1 trial

  18. Pegcetacoplan (APL-2)

    Apellis

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule terminated

    1 trial

  19. PEGCETACOPLAN (APL-2)

    Apellis

    Geographic Atrophy

    phase 1 small molecule completed

    1 trial

  20. Virtual Reality (VR) Contrast Function Test

    Apellis

    Age-Related Macular Degeneration

    other active

    1 trial

Drugs (1)

Search drugs →

  1. pegcetacoplan

    ASPAVELI

    SUBCUTANEOUS approved

    L04AJ03

Patents (8)

Search patents →

  1. US 12290566

    Dosing regimens and related compositions and methods

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12251395

    RNAS for complement inhibition

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11903994

    Dosing regimens

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11844841

    Dosing regimens and related compositions and methods

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11712460

    Methods of treating chronic disorders with complement inhibitors

    Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11661441

    Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11510939

    RNAs for complement inhibition

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11407789

    Cell-penetrating compstatin analogs and uses thereof

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Apellis?

Apellis (APLS) is a pharma company. headquartered in WALTHAM, MA, EU. listed on NYSE. NovaPharmaNews links 20 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Apellis sponsor?

We track 20 ClinicalTrials.gov-linked programs for Apellis, including APL-2 and 19 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Apellis company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.